Combined chemotherapy with gemicitabine and cisplatin as preoperative induction treatment in patients of stage m a( N_2) NSCLC
- VernacularTitle:吉西他滨合用顺铂术前诱导治疗Ⅲa期(N_2)非小细胞肺癌
- Author:
Yongqiang YANG
;
Qingyuan HUANG
;
Deming WANG
- Publication Type:Journal Article
- Keywords:
NSCLC;
gemcitabine;
cisplatin;
neoadjuvant chemotherapy
- From:China Oncology
1998;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose: To study the clinical efficacy, toxicity of preoperative chemotherapy and survival time with Gemicitabine-Cisplatin combination in the treatment of stage Ma( N2) NSCLC. Methods: Thirty patients with stage IIIa( N2) NSCLC were included. Gemicitabine was administered on dl, 8 and 15 at a dose of 1000 mg/m" and Cisplatin at a dose of 100 mg/m on d2. The chemotherapy was repeated every 28days. Results: Thirty patients were evaluable for response. The overall response rate was 70%. Surgical'excision rate after preoperative chemotherapy was 93%. Total surgical excision rate was 70%. Median survival time was 15 months, one year survival rate was 67%. The main toxicity was hematological, thrombocytopenia of grade III-IV appeared in 46% course of treatment, but it did not lead to hemorrhage. Conclusions: Preoperative chemotherapy with Gemicitabine-Cisplatin combination is effective and well-tolerated in the treatment of stage IIIIa( N2) NSCLC. So it is worthy to be further studied and popularized.
